Veterinary anti-infective discovery

Antimicrobial Peptide Screening Platform for Veterinary Pathogens

Advance veterinary antimicrobial peptide candidates with pathogen-panel susceptibility testing, time-kill profiling, serum stability, hemolysis and cytotoxicity assessments, resistance-emergence research, and mechanism-oriented assays. BioVenic connects complementary readouts to help animal-health researchers prioritize peptides for the next stage of preclinical development.

Overview

Choose Antimicrobial Peptide Leads with Evidence Beyond a Single MIC

Early peptide hits can lose apparent activity when the pathogen isolate, serum environment, exposure duration, or host-cell model changes. For veterinary anti-infective research, a useful lead-screening decision therefore requires more than a one-time growth-inhibition result. Activity, killing behavior, stability, and compatibility should be interpreted together against a clearly defined species and infection context.

BioVenic's antimicrobial peptide screening platform offers an adaptable research framework for academic laboratories, veterinary microbiologists, AMR teams, and animal-health discovery programs. Screening packages can begin with a small peptide library and a focused bacterial panel, then expand into kinetic, selectivity, and mechanistic investigations as candidate quality and project feasibility become clearer.

Research service scope

Integrated Veterinary Pathogen Peptide Screening Services

A staged screening strategy helps reduce unnecessary downstream experiments. Each research module can be selected independently or combined into a lead-prioritization program, with appropriate controls, assay acceptance criteria, and reporting expectations agreed during study planning.

Activity

Pathogen-Panel Susceptibility

Screen peptides against selected veterinary bacterial strains and compare inhibitory activity across isolates. MIC and, where appropriate, MBC endpoints support potency ranking, reproducibility assessment, and follow-up prioritization; strains and conditions are specified before study initiation.

Kinetics

Time-Kill and Recovery Profiles

Characterize changes in viable bacterial burden across defined observation points to distinguish rapid killing, delayed suppression, and potential regrowth. Quantitative trends can be evaluated alongside concentration dependence and suitable comparators rather than inferred from MIC values alone.

Exposure

Serum and Matrix Stability

Explore peptide persistence in project-relevant matrices using fit-for-purpose analytical measurements. Stability profiles help flag candidates that require sequence optimization, different experimental conditions, or further formulation consideration before more extensive preclinical evaluation.

Selectivity

Hemolysis and Animal Cell Compatibility

Measure erythrocyte membrane effects and selected host-cell viability signals in species-appropriate systems where available. Activity and compatibility results can be considered together to support preliminary selectivity estimates without equating isolated cell assays with in vivo safety.

Resistance

Resistance-Emergence Assessment

For feasible, approved programs, investigate phenotypic susceptibility shifts after repeated experimental exposure. Interpret the results as an early indicator of resistance risk, alongside strain background and assay conditions; a favorable result cannot establish resistance-proof activity.

Mechanism

Membrane and Mechanism-Oriented Readouts

Use carefully selected membrane permeability, depolarization, or interaction assays to explore whether the observed antimicrobial phenotype is consistent with membrane perturbation. Follow-up studies can help separate a plausible mechanistic hypothesis from direct proof of a molecular target.

Decision guide

Select the Right Assay for Each Lead-Selection Question

A tiered screen separates initial hit finding from the more demanding evidence needed for peptide advancement. Readouts are interpreted in context, not as guarantees of therapeutic performance.

Antimicrobial peptide assays, research questions, and deliverables
Research question Illustrative assay Decision output
Does the peptide inhibit relevant isolates? Susceptibility panel; MIC/MBC where suitable Ranked activity profile and strain-level comparison
Does inhibition translate into killing? Time-kill viable-count analysis Kinetic trajectories and regrowth observations
Can the peptide remain intact in relevant matrices? Serum or matrix stability with analytical detection Stability trend and formulation or optimization flags
Is host-cell compatibility acceptable for follow-up? Hemolysis and selected cell viability assays Safety signals and preliminary selectivity context
What further questions could block progression? Resistance-emergence and mechanism-oriented research Risk flags and prioritized confirmatory experiments
Workflow

From Veterinary Isolate Selection to Lead Prioritization

A connected research sequence with defined decision gates—not a one-size-fits-all protocol.

Scope the Panel

Species, indication, peptide materials, isolate selection, controls, and endpoints.

Screen Activity

Comparative inhibition results and confirmation of promising candidates.

Resolve Risk

Time-kill, stability, hemolysis, and selected host-cell readouts.

Investigate Mode

Optional resistance and mechanism-oriented follow-up assays.

Rank and Report

Integrated candidate evidence, limitations, and proposed next studies.

Decision gate: advance candidates that meet project-defined activity and compatibility expectations; revisit the panel or optimization strategy when data conflict.
Deliverables

Research Outputs Built for the Next Development Decision

BioVenic can structure output around each candidate, veterinary isolate, and assay endpoint. The final deliverable is intended to support research decisions and further experimental planning, rather than provide a clinical efficacy claim.

  • ✓Study design and traceability: agreed panel, sample identifiers, controls, quality checks, and assay scope.
  • ✓Quantitative result tables: candidate-by-isolate activity endpoints, kinetic results, and compatibility observations.
  • ✓Visual research summaries: interpreted curves, comparison graphics, and endpoint-level context.
  • ✓Prioritization rationale: strengths, uncertainties, assay limitations, and suggested follow-up directions.

What to Share When Starting a Project

Peptide inputs

Candidate sequences, molecular modifications, purity, quantity, and any existing screening data.

Pathogen context

Species indication, bacterial taxa, isolate characteristics, and desired comparison groups.

Assay priorities

Target endpoints, relevant matrices, host-cell models, and specific research questions.

Practical constraints

Material availability, biosafety limitations, target decisions, budget, and project schedule.

Scientific literature

Published Data on Antimicrobial Peptide Activity in Veterinary Pathogens

The figure presents quantitative bacterial-growth trajectories for three bovine antimicrobial peptides—BMAP-28, Syn-1, and Bac-5—tested against the veterinary respiratory pathogen Mannheimia haemolytica. The reported curves compare peptide concentrations and starting bacterial burdens over time. In this study, inhibition depended on the candidate and exposure conditions, illustrating why a single endpoint cannot fully describe antimicrobial performance.1

The investigators also evaluated susceptibility endpoints and peptide combinations, demonstrating how isolate-level MIC/MBC measurements complement dynamic growth assessment. Separate published safety research shows that hemolysis can vary between host species, supporting the inclusion of species-relevant compatibility tests.2 Together, these findings inform practical study design for BioVenic's pathogen-panel screening, kinetic profiling, and preclinical lead-ranking services.

Published time-course bacterial count plots comparing antimicrobial peptide effects on Mannheimia haemolytica in bovine pathogen research. (OA Literature)
Fig.1 Antimicrobial effect of synthetic peptides on Mannheimia haemolytica bacterial growth over time; original figure reproduced without modification from Cornejo et al. (2024). 1,3

Our Advantages in Veterinary Antimicrobial Peptide Screening

A focused, configurable evaluation strategy for animal-health R&D teams.

Veterinary Context

Panels reflect the intended host species, pathogen, and research question.

Connected Readouts

Activity, kinetics, stability, and compatibility are interpreted as complementary evidence.

Phased Study Design

Follow-up experiments are prioritized by candidate signals and project needs.

Actionable Reporting

Integrated datasets highlight limitations, risk flags, and next research decisions.

Frequently Asked Questions

Panels are scoped to the project and organism availability. Researchers can propose relevant Gram-positive and Gram-negative veterinary bacterial isolates, including reference strains and characterized field isolates where feasible. Species, isolate provenance, handling requirements, and the intended animal indication guide the final design.

References

  1. Cornejo, Santiago, et al. "Synthetic antimicrobial peptides Bac-5, BMAP-28, and Syn-1 can inhibit bovine respiratory disease pathogens in vitro." Frontiers in Veterinary Science 11 (2024): 1430919. https://doi.org/10.3389/fvets.2024.1430919
  2. Greco, Ines, et al. "Correlation between hemolytic activity, cytotoxicity and systemic in vivo toxicity of synthetic antimicrobial peptides." Scientific Reports 10 (2020): 13206. https://doi.org/10.1038/s41598-020-69995-9
  3. Distributed under Open Access license CC BY 4.0, without modification.
Get a quote

We're excited to learn more about your project and provide you with a customized quote tailored to your needs. Please fill out the form below, and we'll get back to you as soon as possible.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inquiry Basket